The Biomarker Bottleneck in Immuno-oncology: Understanding to Overcome

The Scientist is bringing together a panel of experts to discuss their research and provide insight into how this issue is being overcome.

Oct 29, 2018
The Scientist Creative Services Team

 

FREE Webinar

Wednesday, January 23, 2019
2:30-4:00 PM Eastern Time
Register Now

In recent years an avalanche of new compounds have been developed for the treatment of cancer with immunotherapy. However, novel biomarkers are required to guide treatment with these new compounds. The complexity of cancer and the immune response mean predictive biomarkers for immuno-oncology can differ vastly between people and cancer subtypes. New approaches for biomarker discovery include using next-generation gene expression profiling, which allows patient-level biomarker determination, as well as multiplex spacial protein profiling to identify protein targets including immune cell markers and checkpoint proteins. To delve deeper into the biomarker bottleneck, The Scientist is bringing together a panel of experts to discuss their research and provide insight into how this issue is being overcome.

Topics to be covered:

  • Assessing heterogeneity of immune cell infiltration in tumors to predict response to cancer immunotherapy
  • TBD

Register Now

Meet the Speakers:

Alice O. Kamphorst, PhD
Assistant Professor of Oncological Sciences
Precision Immunology Institute
Icahn School of Medicine at Mount Sinai